Abstract
On the basis of preliminary in vitro data, we evaluated E-1040, a new cephalosporin, against 188 cystic fibrosis (CF) sputum isolates obtained from 26 CF centers in the United States. These isolates included mucoid and nonmucoid Pseudomonas aeruginosa, Pseudomonas cepacia, Staphylococcus aureus, Haemophilus influenzae, and Escherichia coli. In addition to MICs measured under standard conditions, selected isolates were tested at various pH values, inoculum sizes, and diluent (CF serum and sputum) conditions. E-1040 activities (MICs for 50 and 90% of the strains) against the isolates were as follows: P. aeruginosa (mucoid and nonmucoid), 1 and 4 micrograms/ml; P. cepacia, 4 and 16 micrograms/ml; S. aureus, 8 and 8 micrograms/ml; H. influenzae, 1 and 4 micrograms/ml; and E. coli, less than or equal to 0.12 and less than or equal to 0.12 microgram/ml. E-1040 activity against mucoid P. aeruginosa was 4-fold greater than that of aztreonam, 16-fold greater than that of ceftazidime, and 32-fold greater than that of piperacillin. E-1040 was similar to other broad-spectrum cephalosporins against S. aureus, H. influenzae, and E. coli. Bactericidal activity was less than or equal to 1 dilution of MIC for 88% of the strains, although kinetic studies with mucoid strains of P. aeruginosa demonstrated effective killing only at eight times the MIC. Variations in pH from 5 to 8, in inoculum size from 10(3) to 10(7) CFU/ml, and in diluent (CF serum or CF sputum) did not affect E-1040 activity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodey G. P., Pan T. Effect of cephalothin on growth patterns of micro-organisms. J Antibiot (Tokyo) 1976 Oct;29(10):1092–1095. doi: 10.7164/antibiotics.29.1092. [DOI] [PubMed] [Google Scholar]
- Bundtzen R. W., Gerber A. U., Cohn D. L., Craig W. A. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981 Jan-Feb;3(1):28–37. doi: 10.1093/clinids/3.1.28. [DOI] [PubMed] [Google Scholar]
- Govan J. R. Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production. J Med Microbiol. 1975 Nov;8(4):513–522. doi: 10.1099/00222615-8-4-513. [DOI] [PubMed] [Google Scholar]
- Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krieg D. P., Bass J. A., Mattingly S. J. Aeration selects for mucoid phenotype of Pseudomonas aeruginosa. J Clin Microbiol. 1986 Dec;24(6):986–990. doi: 10.1128/jcm.24.6.986-990.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakashima M., Uematsu T., Kanamara M., Ueno K., Setoyama T., Tomono Y., Ohno T., Okano K., Morishita N. Phase I study of E1040, a new parenteral cephem antibiotic. J Clin Pharmacol. 1989 Feb;29(2):144–150. doi: 10.1002/j.1552-4604.1989.tb03303.x. [DOI] [PubMed] [Google Scholar]
- Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Watanabe N., Katsu K., Moriyama M., Kitoh K. In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693–701. doi: 10.1128/aac.32.5.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilson D. A., Rolinson G. N. The recovery period following exposure of bacteria to penicillins. Chemotherapy. 1979;25(1):14–22. doi: 10.1159/000237817. [DOI] [PubMed] [Google Scholar]